Key Points
- Insider sale: Director Marcella Ruddy sold 1,065 shares on May 4 at an average price of $30.00 (proceeds ~$31,950) under a pre-arranged Rule 10b5-1 plan, reducing her stake by 1.55% to 67,682 shares (≈$2.03M).
- Stock snapshot: NASDAQ:TECX opened at $29.02, with a 52-week range of $14.39–$36.03 and a market cap of about $547M; the stock trades above its 200-day SMA (~$23.28) and near its 50-day SMA (~$29.40).
- Analyst and ownership context: Analyst views are mixed but average to a “Moderate Buy” with an average target of $80.57, and institutional investors own roughly 62.63% of the shares.
Tectonic Therapeutic, Inc. (NASDAQ:TECX - Get Free Report) insider Marcella Ruddy sold 1,065 shares of the business's stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $30.00, for a total value of $31,950.00. Following the completion of the transaction, the insider owned 67,682 shares in the company, valued at approximately $2,030,460. This trade represents a 1.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Tectonic Therapeutic Stock Performance
NASDAQ:TECX opened at $29.02 on Thursday. Tectonic Therapeutic, Inc. has a one year low of $14.39 and a one year high of $36.03. The business's 50-day simple moving average is $29.40 and its 200 day simple moving average is $23.28. The stock has a market cap of $547.03 million, a price-to-earnings ratio of -7.17 and a beta of 3.27.
Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.11) by $0.08. On average, equities research analysts predict that Tectonic Therapeutic, Inc. will post -4.86 EPS for the current year.
Analysts Set New Price Targets
Several research analysts recently commented on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Tectonic Therapeutic in a research note on Tuesday, April 21st. Wall Street Zen downgraded shares of Tectonic Therapeutic from a "sell" rating to a "strong sell" rating in a research note on Saturday, April 18th. Lifesci Capital upgraded shares of Tectonic Therapeutic to a "strong-buy" rating in a research note on Thursday, February 5th. Truist Financial reduced their price objective on shares of Tectonic Therapeutic from $64.00 to $60.00 and set a "buy" rating on the stock in a research note on Thursday, January 8th. Finally, Stifel Nicolaus initiated coverage on shares of Tectonic Therapeutic in a research note on Monday, April 13th. They set a "buy" rating and a $75.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $80.57.
Get Our Latest Stock Analysis on TECX
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in TECX. Caitong International Asset Management Co. Ltd grew its position in shares of Tectonic Therapeutic by 451.6% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 3,966 shares of the company's stock worth $62,000 after acquiring an additional 3,247 shares in the last quarter. New York State Common Retirement Fund acquired a new position in shares of Tectonic Therapeutic in the 2nd quarter worth approximately $99,000. China Universal Asset Management Co. Ltd. grew its position in shares of Tectonic Therapeutic by 83.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 6,880 shares of the company's stock worth $108,000 after acquiring an additional 3,130 shares in the last quarter. AlphaQuest LLC grew its position in shares of Tectonic Therapeutic by 208.6% in the 3rd quarter. AlphaQuest LLC now owns 7,299 shares of the company's stock worth $115,000 after acquiring an additional 4,934 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Tectonic Therapeutic in the 2nd quarter worth approximately $119,000. Institutional investors and hedge funds own 62.63% of the company's stock.
About Tectonic Therapeutic
(
Get Free Report)
Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
